Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;53(3):104245.
doi: 10.1016/j.lpm.2024.104245. Epub 2024 Sep 5.

Duration of anticoagulation of venous thromboembolism

Francis Couturaud  1 , Nicolas Meneveau  2 , Marie Antoinette Sevestre  3 , Pierre-Emmanuel Morange  4 , David Jimenez  5
Affiliations
Review

Duration of anticoagulation of venous thromboembolism

Francis Couturaud et al. Presse Med. 2024 Sep.

Abstract

Venous thromboembolism (VTE) is a common, serious condition that requires anticoagulation for at least three months to prevent recurrence and long-term complications. After this initial period, the decision to continue or stop anticoagulation depends on the balance between the risk of recurrent VTE and the risk of bleeding. Established guidelines suggest short-term anticoagulation for VTE caused by transient factors and indefinite anticoagulation for recurrent or cancer-associated VTE. However, for a first unprovoked VTE, decision-making remains challenging. Current predictive scores for recurrence and bleeding are not sufficiently reliable, and the safety and efficacy of reduced-dose anticoagulation remain unclear. In the future, precision and patient-centred medicine may improve treatment decisions in this area.

Keywords: Anticoagulant-related bleeding; Direct oral anticoagulants; Recurrent venous thromboembolism; Thrombophilia; Venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr. Couturaud reports having received research grant support from Bayer, Bristol-Myers Squibb/Pfizer, Merck Sharp and Dohme and fees for board memberships or symposia from Bayer, Bristol-Myers Squibb/Pfizer, Merck Sharp and Dohme, GlaxoSmithKline, Chiesi and Astra Zeneca and having received travel support from Bayer, Bristol-Myers Squibb/Pfizer, Merck Sharp and Dohme, Leo Pharma, Sanofi, Chiesi. Dr.Morange reports having research grant support from Bristol-Myers Squibb and fees for board memberships or symposia from Bayer, Bristol-Myers Squibb/Pfizer and Sanofi. Dr Sevestre reports fees and travel support from Bristol-Myers Squibb, Viatris, Leo Pharma and Novartis. Dr. Meneveau declares he has no conflict of interest.

MeSH terms

LinkOut - more resources